No internet connection — showing the saved version of the page.

Bright Minds Bios…

USUSD
← to the screener
US:DRUGCN:DRUG

Bright Minds Biosciences Inc (US:DRUG) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
brightmindsbio.com
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
CHICAGO, United States
Management
Ian McDonald
Employees
26
Shares outstanding
9.86 M
Free float
6.69 M
Market cap
500.21 M USD
Insiders
11.94%
Institutions
94.95%
Industry (SIC)
Pharmaceutical Preparations
P/E
loss
EPS
−2.05 USD
P/B
0.94
ROE
−14.6%
FCF
−24.7 M CAD
Debt
65.6 K CAD
negative FCF — not covered
Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
NAV
31.37 CAD · P/NAV 0.94
Balance sheet date30.06.2026
Assets310 M CAD
− Liabilities2.54 M CAD
= NAV (equity of the company's shareholders)308 M CAD
= Tangible NAV308 M CAD
Shares9 812 061
NAV per share31.37 CAD
Tangible NAV per share31.37 CAD
Share price (DRUG)20.7000 USD
P/NAV0.94
NAV history
Balance sheet dateNAVNAV per share
30.06.2026308 M CAD31.37 CAD
31.03.2026309 M CAD31.44 CAD
31.12.202589.3 M CAD11.47 CAD
30.09.202582.0 M CAD10.74 CAD
30.06.202551.8 M CAD7.32 CAD
30.09.20245.54 M CAD1.22 CAD
Description

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksDRUG primaryUSD20.7 -0.29%common stock
CN Canadian Securities ExchangeDRUG secondaryCAD77.76 +2.48%common stock

Price

Hover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
Jupiter Topco LLC13.86%1.35 M2026-06-30
McDonald (Ian) (Director…≈10.34%1.01 M2026-06-12
Cormorant Asset Manageme…≈9.76%950 0002026-04-28
Cormorant Asset Manageme…9.25%900 0002026-06-30
Blackrock Inc.7.05%686 1842026-06-30
Vivo Capital, LLC5.73%557 1722026-06-30
Vestal Point Capital, LP5.6%545 0002026-06-30
Braidwell LP4.97%483 8222026-06-30
Driehaus Capital Managem…4.45%433 3772026-06-30
Balyasny Asset Managemen…3.55%345 0532026-06-30
Adage Capital Partners G…3.44%335 0002026-06-30
Point72 Asset Management…3.36%327 4162026-06-30
iShares Trust-iShares Ru…1.97%191 5122026-08-31
MUTUAL FUND SERIES TRUST…1.34%130 0132026-06-30
BlackRock Funds-BlackRoc…0.98%95 6552026-05-31
Fidelity Salem Street Tr…0.83%81 2312026-07-31
iShares Trust-iShares Ru…0.72%70 1252026-08-31
Fidelity Covington Trust…0.55%53 3282026-09-30
Driehaus Mutual Funds-Dr…0.43%41 5682026-06-30
AdvisorShares Trust-Advi…0.41%39 8222026-09-30
VANGUARD SCOTTSDALE FUND…0.37%35 8792026-05-31
BlackRock Health Science…0.33%31 9332026-06-30
Fryzuk (Jeremy) (Directo…≈0.31%30 6092026-02-24
Vasilkevich (Alex) (Seni…≈0.22%21 7502026-05-28
Bottler (Nils Christian)…≈0.05%5 0002026-06-03
Cheung (Ryan) (Senior Of…≈0%4002026-10-06